Pfizer (PFE) AGM 2026 summary

Opening remarks and agenda

• The meeting was called to order with a welcome, introduction of key participants, and an overview of meeting procedures, including Q&A logistics and voting protocols.

Financial performance review

• 2025 financial commitments were met, with revenues and adjusted EPS exceeding expectations despite low COVID-19 activity.

• $9.8 billion was returned to shareholders via quarterly dividends in 2025.

• Recently launched and acquired products grew by 14% operationally, delivering $10.2 billion in revenue.

• $7.2 billion in anticipated net cost savings from productivity programs targeted by end of 2026.

Board and executive committee updates

• The board consists of 12 directors, all standing for re-election, with diverse expertise in finance, science, operations, and technology.

• Board oversight and accountability were highlighted as key to strategic execution.